Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1182/blood-2016-11-749366 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Recombinant human thrombopoietin improves hematopoietic stem cell differentiation and T-cell immune homeostasis in patients with severe aplastic anemia by upregulating c-MPL.
Front Pharmacol
August 2025
Department of Hematology, Tianjin Medical University General Hospital, Tianjin, China.
Background: Recombinant human thrombopoietin (rhTPO) regulates platelet production by promoting megakaryocyte proliferation and has shown promising therapeutic effects in hematopoietic recovery for severe aplastic anemia (SAA). However, its potential impact on immune cells remains unclear.
Methods: This study included 23 patients with SAA, who were divided into two groups based on whether they received rhTPO.
Composite Scaffolds of Decellularized Placenta/PRP Enhance the Differentiation of Adipose Tissue-Derived Mesenchymal Stem Cells Into Insulin-Producing Cells In Vitro.
J Biomed Mater Res B Appl Biomater
September 2025
Fertility and Infertility Research Center, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran.
In the current in vitro experiment, we fabricated and characterized placenta/platelet-rich plasma (PL/Pt) composite scaffolds and evaluated their effect on differentiating adipose stem cells (ASCs) into insulin-producing cells (IPCs) in vitro. The human placenta (PL) was decellularized (dPL), characterized, and digested in pepsin. PRP was extracted using a two-step centrifugation process and then freeze-dried.
View Article and Find Full Text PDFImpact of Dara-VTD induction therapy on stem cell mobilization outcomes in newly diagnosed multiple myeloma patients undergoing autologous stem cell transplantation: a multicenter study.
Ann Hematol
September 2025
Hematology Unit, Department of Clinical Medicine and Surgery, University of Naples "Federico II", Naples, Italy.
Daratumumab combined with bortezomib, thalidomide, and dexamethasone (Dara-VTD) is a highly effective induction therapy for newly diagnosed multiple myeloma (NDMM) patients eligible for autologous stem cell transplantation (ASCT). However, its impact on stem cell mobilization requires a critical evaluation. This study examines the effects of Dara-VTD on stem cell mobilization and collection outcomes.
View Article and Find Full Text PDF[Clinical analysis of donor-purified CD34(+) stem cell boost in 11 patients with poor hematopoietic reconstruction after haploid hematopoietic stem cell transplantation for aplastic anemia].
Zhonghua Xue Ye Xue Za Zhi
July 2025
Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing 100044, China.
To evaluate the safety and efficacy of donor-purified CD34(+) stem cell boosts in patients with poor hematopoietic reconstruction (PHR) after haploid hematopoietic stem cell transplantation (haplo-HSCT) for aplastic anemia (AA) . A retrospective analysis was conducted on 11 patients with AA and PHR who underwent haplo-HSCT and received donor-purified CD34(+) stem cell boosts at Peking University People's Hospital. Recovery of blood cell counts, incidence of graft-versus-host disease (GVHD), and overall survival (OS) were assessed.
View Article and Find Full Text PDFBackground: Delayed platelet engraftment (DPE) after allo-HSCT lacks standard therapy. Avatrombopag (AVA), a second-generation TPO agonist, is often delayed until transfusion-related events occur, potentially harming high-risk recipients.
Objectives: We compared recombinant human thrombopoietin (rh-TPO) with early AVA switching for treating DPE in aplastic anemia (AA) patients post-allo-HSCT to optimize management strategies.